Rationale: Prognostication is important when counseling patients and defining treatment strategies in pulmonary arterial hypertension (PAH).
Measurements and Main Results: During the follow-up period of 42 (range, 17-142) months 576 patients were studied and 221 (38%) died. A derivation cohort (n = 288; 115 deaths) and validation cohort (n = 288; 106 deaths) were identified. We used multivariate Cox regression and found two independent MRI predictors of death (P , 0.01): right ventricular end-systolic volume index adjusted for age and sex, and the relative area change of the pulmonary artery. A model of MRI and clinical data constructed from the derivation cohort predicted mortality in the validation cohort at 1 year (sensitivity, Over the last two decades there has been significant progress in the treatment of pulmonary arterial hypertension (PAH) but despite this it remains a progressive life-shortening condition. Assessment of disease severity and estimating life expectancy is an important part of patient evaluation. It aids selection of treatment strategy, timing of transplantation, and counseling of patients (1) .
Changes in the pulmonary vasculature in PAH cause an increase in right ventricular (RV) afterload, a reduction in cardiac output resulting in increasing breathlessness, and a fall in exercise capacity (2) . Several measurements have been used to assess disease severity and estimate prognosis and include parameters reflecting symptomatic limitation (World Health Organization [WHO] function class [3] ), impairment of RV function (elevated right atrial pressure [3] [4] [5] , reduced cardiac output [4] [5] [6] , and reduced mixed venous oxygen saturation [5] ), and measurements of exercise capacity (6-minute-walk-test distance) (5, 6) , and maximal oxygen uptake measured using cardiopulmonary exercise testing (7) . In addition, multiparametric equations have been developed to improve the assessment of disease severity and aid prognostication (8, 9) . All of these approaches are limited in part by inherent problems with reproducibility, subjective interpretation, and the invasive nature of investigations, such as cardiac catheterization.
Magnetic resonance imaging (MRI) provides accurate and reproducible information on cardiac morphology and function (10) (11) (12) and in addition also has sensitivity to changes in the pulmonary vasculature (13) (14) (15) (16) . Recently several studies have evaluated MRI as a tool to assess for the presence of PAH (14, 15, (17) (18) (19) (20) (21) . In addition, studies have evaluated the prognostic value of MRI measurements; RV end-diastolic volume (RVEDV) and RV end-systolic volume (RVESV), RV ejection fraction (RVEF), and more recently RVpulmonary artery (PA) coupling metrics and PA relative area change (13, 16, (22) (23) (24) (25) have all been shown to have predictive value in patients with PAH. However, these studies have often been performed in relatively small numbers of patients and have concentrated on a limited number of parameters. The aim of this study was to investigate the prognostic value of combined cardiopulmonary MRI metrics in a large PAH registry.
Methods

Patients
Consecutive patients diagnosed with PAH at a pulmonary hypertension referral center, who underwent MRI, were identified from January 2008 to February 2015. Patients referred with suspected pulmonary hypertension underwent systematic evaluation as previously described in the ASPIRE (Assessing the Spectrum of Pulmonary Hypertension Identified at a Referral Centre) registry (26) , including lung function, exercise testing, highresolution computed tomography and computed tomography pulmonary angiography, MRI, and right heart catheterization. Treatment at the time of census or death was recorded as oral monotherapy (phosphodiesterase-5 inhibitor or endothelin receptor antagonist), oral combination therapy (phosphodiesterase-5 inhibitor and endothelin receptor antagonist), prostanoid therapy, or calcium channel blocker therapy. Ethical approval for this analysis of imaging techniques and routinely collected data was granted by our institutional review board (ref c06/Q2308/8).
MRI Acquisition
MRI was performed using an eight-channel cardiac coil on a GE HDx (GE Healthcare, Milwaukee, WI) whole-body scanner at 1.5 T. Short-axis cine images were acquired using a cardiac gated multislice balanced SSFP sequence (20 frames per cardiac cycle; slice thickness, 8 mm; field of view, 48; matrix, 256 3 256; BW, 125 kHz/pixel; TR/TE, 3.7/1.6 ms). A stack of images in the short-axis plane with slice thickness of 8 mm (2-mm inter-slice gap) were acquired fully covering both ventricles from base to apex. End-systole was considered to be the smallest cavity area. End-diastole was defined as the first cine phase of the R-wave triggered acquisition or largest volume. Through plane phase contrast imaging was performed orthogonal to the main pulmonary trunk. Phase contrast imaging parameters were as follows: repetition time, TR 5.6 ms; echo time, TE 2.7 ms; slice thickness, 10 mm; field of view, 48 cm, bandwidth, 62.5 kHz; matrix, 256 3 128; 20 reconstructed cardiac phases; and velocity encoding of flow, 150 cm/s. Patients were in the supine position with a surface coil and with retrospective ECG gating.
Image Analysis
Image analysis was performed on a GE Advantage Workstation 4.1 with the observer blinded to the patient clinical information, and cardiac catheter parameters. Right and left endocardial and epicardial surfaces were manually traced from the stack of short-axis cine images, using proprietary MR workstation software to obtain RVEDV and RVESV, and left ventricular (LV) end-diastolic volume (LVEDV) and LV end-systolic volume (LVESV). From end-diastolic and end-systolic volumes, RVEF and LV ejection fraction and RV and LV stroke volume (SV) were calculated. With the exception of RVEF and LV ejection fraction, these measurements were indexed for body surface area. Based on previous work, SV was considered to be the most accurate from LV volumetry (27) and was used for MRI estimation of RV-PA coupling. For calculation of ventricular mass the interventricular septum was considered as part of the LV. RV end-diastolic mass (RV mass) and LV end-diastolic mass were derived (LV mass). Ventricular mass index was defined as RV mass divided by LV mass, as previously described (18) . Maximal and minimal PA areas were measured, and relative area change was defined by the following equation: relative area change = (maximum area 2 minimum area)/minimum area ( Figure 1) (14, 28) .
Right Heart Catheterization and Clinical Assessment
Right heart catheterization was performed using a balloon-tipped 7.5F thermodilution catheter (Becton-Dickinson, Franklin Lakes, NJ). Right heart catheterization was usually performed via the internal jugular vein using a Swan-Ganz catheter. Features at right heart catheterization required to define PAH were mean PA pressure (mPAP) greater than or equal to 25 mm Hg at rest with a pulmonary arterial wedge pressure (PAWP) of less than or equal to 15 mm Hg (29) . Pulmonary vascular resistance (PVR) was determined as follows: PVR = (mPAP 2 PAWP)/cardiac output. Cardiac output was measured by thermodilution technique. Diagnostic classification of the form of PAH was made using standard criteria after multiprofessional assessment (26) . To be included in the study patients were also required to have received treatment with PAH therapy during the study period.
Coupling Measurements
As previously described, RV elastance (Ees) was estimated as mPAP divided by RVESV index (30) . Pulmonary arterial elastance (Ea) was estimated using mPAP 2 PAWP divided by SV index. Therefore, Ees/Ea by a combined right heart catheterization and MRI approach was defined as follows: (mPAP/RVESV index)/[(mPAP 2 PAWP)/SV index]. MRI estimated Ees/Ea was defined by SV/RVESV (24, (30) (31) (32) . Table 1 summarizes the coupling measurements and pulmonary arterial relative area change metrics.
Statistics
The interval from evaluation with MRI until all-cause death or July 15, 2016, was regarded as the follow-up period. Individual analyses of mortality at 1 and 3 years were also performed. Log-log plots were produced for each variable to assess proportional hazards; continuous variables reference category for multivariate analysis and combination therapy, being the largest therapy group, was used as the reference category for multivariate analysis. Derivation and validation cohorts were constructed to develop models encompassing MRI data alone and MRI and clinical data combined. Patients were assigned a study number based on the date of the MRI study, with the first patient scanned assigned a number of n = 1 and the last patient scanned assigned a number of n = 576. Those with an odd number were assigned to the derivation cohort and those with an even number were assigned to the validation cohort.
In the derivation cohort variables significant at a univariate P less than 0.2 were entered into a multivariate Cox proportional hazards regression model. The model was used to predict outcome in the validation cohort. Kaplan-Meier plots were constructed to illustrate the prognostic value of MRI volumetric measurements using median threshold values. Groups were compared using the log-rank (Mantel-Cox) test. Receiver operating characteristic (ROC) analysis was used to assess prognostic significance of candidate predictors of mortality with area under the curve (AUC) data presented for mortality at 1 and 3 years. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were derived from the 2 3 2 prediction table. For ROC comparison we have used a nonparametric method analogous to the Wilcoxon/MannWhitney test as previously described (35) . The derivation cohort was used to develop predictive thresholds for CMR parameters.
In addition, Bonferroni correction was performed on the univariate candidate predictors of mortality (n = 32) and variables that reached statistical significance P less than 0.0016 are shown in Table 2 . Interobserver and intraobserver reproducibility was tested in 30 randomly selected cases using intraclass correlation coefficient. Statistical analysis was performed using SPSS 19 (SPSS, Chicago, IL) and for presentation of the data GraphPad Prism 6.04 (GraphPad Software, San Diego, CA) software was used. A P value less than 0.05 was considered statistically significant.
Results
A total of 576 patients with PAH were identified. A total of 398 patients were incident and treatment naive, and 178 patients were prevalent patients with PAH on PAH therapy (Figure 2 ). Table 3 shows the demographic, MRI, and right heart catheterization data for (1) the total study cohort, (2) incident patients with PAH who were treatment naive, and (3) prevalent patients with PAH on PAH treatment. The study group included 260 patients with IPAH; 195 patients with PAH associated with connective tissue disease (CTD); 63 patients with congenital heart disease; and 58 patients with PAH associated with HIV, portal hypertension, or drugs and toxins. Table 4 summarizes the baseline characteristics of incident treatment-naive patients with IPAH and PAH-CTD.
Survival Analyses
Full cohort. During the follow-up period 221 patients (38%) died (mean follow-up, 42 mo; range, 17-142). (all P , 0.0001) were also predictive of mortality, all remaining significant after Bonferroni correction. PA relative area change and distensibility were highly correlated (r = 0.88; P , 0.0001). In the multivariate analysis increased RVESVI %pred (P = 0.005) reduced PA relative area change (P = 0.008), age greater than 50 (P , 0.0001), the presence of CTD (P = 0.039), and decreased S v O 2 (P = 0.006) and oral monotheray as compared with combination oral therapy (P = 0.006) were associated with worse outcome. Figure 3 shows Kaplan-Meier plots for RVESVI % pred and PA relative area change above and below median thresholds.
Incident and prevalent cases. Incident treatment-naive patients were older (P , 0.0001) ( Table 3 ) and had worse outcome at Cox regression analysis (hazard ratio, 2.338; 95% confidence interval [CI], 1.603-3.408; P , 0.0001) than prevalent patients with PAH on therapy. Incident patients had more severe hemodynamic impairment with lower S v O 2 (P = 0.003) and cardiac index (P , 0.0001) and on MRI had evidence of more severe disease with higher RVESVI %pred (P , 0.0001) and lower RVEF %pred, LVEDV %pred (P , 0.0001), and PA relative area change (P , 0.0001) ( Table 3 ). In the multivariate Cox regression analysis of incident patients the same predictors were significant as in the full cohort inclusive of incident and prevalent cases. Age greater than 50, lower S v O 2 , and lower PA relative area change were independent indicators of adverse outcome; lower RVESVI %pred and combination oral therapy predicted improved survival (Table 5 ). 
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Swift, Capener, Johns, et al.: MRI Predicts Outcome in Pulmonary Hypertensionmultivariate analysis: RVESVI %pred (P = 0.001), Ees (P = 0.035), low S v O 2 (P = 0.002), age greater than 50 (P = 0.010), and male sex (P = 0.029) ( Table 5) . At ROC analysis, RVESVI %pred was predictive of mortality in patients with IPAH at 1 and 3 years (AUC, 0.716 and 0.735, respectively). In incident treatment-naive patients with PAH-CTD, PA stiffness measured by PA relative area change (P = 0.003) and Ees/Ea (combined invasive/noninvasive metric; P = 0.010) and treatment (oral monotherapy as compared with combination therapy; P = 0.019) were independent predictors of outcome at multivariate analysis (Table 5 ). In PAH-CTD PA relative area change was predictive of mortality at 1 and 3 years (AUC of 0.640 and AUC of 0.696, respectively).
Prognostic model and validation. A derivation cohort (n = 288; 115 deaths) and validation cohort (n = 288; 106 deaths) were identified. There was no significant difference in age, sex, WHO functional class, MRI data, right heart catheter hemodynamics, time to death or census, or the proportion of CTD, IPAH, or congenital heart disease or male patients between the validation and derivation cohorts (all P . Table 6 presents the sensitivity, specificity, PPV, and NPV data for these optimal thresholds for 3-year mortality. There was no significant difference at ROC analysis for predicting mortality between current methods of correcting MRI data for age, sex, and body size (Maceira and coworkers [33] and Kawut and coworkers [34] ); RVEDV (P = 0.955); RVEF (P = 0.236); and RVEDM (P = 0.635).
Reproducibility of MR indices.
Excellent interobserver reproducibility was identified for RVEDV and RVESV measurements; with high intraclass correlation coefficients (ICC) demonstrated, 0.959 and 0.991, respectively. The agreement was found to be marginally weaker for RVEF and SV measurements 0.957 and 0.928, respectively. Excellent interobserver reproducibility was identified for LV volume and LV function ICC 0.953-0.988. High intraobserver agreement for RV volume and function measurements was shown (ICC 0.940-0.996), and similarly high intraobserver agreement was found for LV volume measurements (ICC 0.973-0.986). MRI estimated Ees/Ea had high interobserver and intraobserver reproducibility, ICC 0.938 and 0.977, respectively. PA relative area change had high interobserver and intraobserver reproducibility, ICC 0.891 and ICC 0.900, respectively.
Discussion
This study confirms the independent prognostic value of MRI measurements reflecting RV volume and stiffness of the proximal pulmonary vasculature in a large cohort of patients with PAH. In addition, a model combining MRI measurements of RVESV (%pred) and PA relative area change in combination with clinical data (age, sex, WHO function class, and the presence or absence of an underlying CTD), improves prognostication in PAH.
Many indices of RV size and function have been proposed as prognostic markers in the patients with pulmonary hypertension; however, previous studies have often been performed in comparatively small cohorts of patients. Given the large number of patients in the current study and the number of deaths during the follow-up period it has provided an opportunity to assess the relative value of a number of candidate MRI prognostic markers. This study confirms the prognostic value of RV volumes and ejection fraction measured at MRI shown in previous studies (23, 25) . Although in clinical practice physicians have traditionally favored single measurements, such as RVEF, this study demonstrates the added prognostic value of combining a measure of the RV (RVESVI %pred) and a measure of changes in the proximal pulmonary vasculature (PA relative area change). A criticism of relatively simple measures thought to reflect RV function, such as volumes and ejection fraction, is that these metrics are not load independent (36) . Recently more complex measurements reflecting RV-PA coupling, described by the simultaneous relationship between two load independent metrics, RV contractility (Ees) and afterload (Ea) (36) , have been proposed as superior to volumetric measurements. Previous work has shown that parameters, such as Ees and Ea, can be estimated from standard data collected from right heart catheterization and MRI (30) , rather than using conductance catheters not typically used in routine clinical practice. In the current study, in patients with PAH-CTD combined MRI and right heart catheterization Ees/Ea was independently predictive of mortality although not found to be independently prognostic in the full cohort. In addition, a completely noninvasive MR-based approach and techniques using gated blood pool scintingraphy can yield measures of RV-PA coupling acknowledging previously described limitations (24, (30) (31) (32) 37) . A recent study has shown the superior prognostic significance of an MRI-derived estimate of RV-arterial coupling Ees/Ea over other invasive and noninvasive measures of RV function (24) . However, no additional prognostic value of an MRI-only measurement of RV-PA coupling over volumetric indices was demonstrated in the present study.
Independent prognostic markers differed between IPAH and PAH-CTD. In IPAH measures of RV size and function, RVESV % predicted, and Ees were independently prognostic, in addition to age, sex, and S v O 2 . Whereas, independent prognostic markers in PAH-CTD were pulmonary arterial relative area change and Ees/Ea (combined invasive/MRI). These differences are likely to reflect the individual pathophysiology and therapy responsiveness of PAH subgroups and reinforces that subgroups have differing prognostic markers. In contrast, to a previous study by Tedford and coworkers (38) we found patients with PAH associated with CTD had higher contractive RV function (Ees) relative to afterload (Ea). We estimated coupling indices using hemodynamic data collected from standard right heart catheterization studies and MRI and did not perform dedicated pressurevolume studies. There are assumptions made using simplified measures of coupling and differences in the populations in these two studies may explain these disparities. Further research studying RV adaption to elevated afterload in these subgroups is warranted.
PA relative area change was found to be an independent prognostic marker in the full cohort, and our data suggest that the stiffness of the pulmonary vasculature has independent prognostic value in addition to baseline measurements reflecting RV function. The present study shows comparable univariate prognostic value of noninvasive PA relative area change and PA distensibility, and no significant difference at ROC analysis between the two measures. This may reflect the close correlation between these two metrics (r = 0.88).
Patient age has been shown to strongly predict mortality in several PAH cohorts (39, 40) . These studies have also demonstrated that the range and average age of patients has risen significantly over the last decade making adjustments for age and sex more relevant in the current era for accurate individual risk stratification (41) . RVESV corrected for age, sex and body surface was a significantly stronger predictor of mortality than when adjusted for body surface area alone, highlighting the need to adjust volumetric measurements for individual patients. We have corrected our data using data by Maceira et al (33) due to similarity in RV analysis technique for the main analyses, however, other normative RV data, such as Kawut et al (34) , is available and demonstrated similar prognostic value in our cohort of patients. In the present study RVESVI %pred rather than RVEDV %pred was independently prognostic; increased RVESV implies enlargement of the RV in addition to a loss of systolic function and may explain the greater prognostic importance. This finding mirrors data in chronic heart failure, in which increasing RVESV has been shown to be an independent predictor of mortality (42) .
In the present study patients on monotherapy with a phosphodiesterase inhibitor or endothelin receptor antagonist had a worse outcome than patients on a phosphodiesterase inhibitor and endothelin receptor antagonist in combination, with the patients in this study receiving sequential rather than upfront combination. Although this is a retrospective study, it is consistent with a prospective double-blinded study, which showed the benefit of sequential combination therapy over monotherapy in patients with PAH (43) in reducing clinical worsening and a MRI focused study of up front combination therapy in systemic sclerosis which demonstrated improvements in RV function (44) . Despite improved outcomes PAH remains a life shortening condition and identification of reproducible and prognostic end-points in PAH will help to assess the value of new therapeutic agents (45) .
In clinical practice, assessments are based on integrating available information and there has been a move toward developing scoring systems to aid prognostication. ROC curves are frequently used to assess the value of diagnostic tests, however, there is only limited data on assessing the prognostic value of candidate prognostic markers in PAH using ROC analysis. The prognostic value of a single MRI measurement was improved by combining MRI metrics and further improved by incorporating additional clinical data, obtaining ROC values equal to or better than previous studies in cardiac disease that estimate cardiovascular risk (46) . However, the value of predictive models depends on the clinical context. In PAH high levels of predictive accuracy are required when deciding on lung transplant or commencing IV prostanoid therapy and this is more immediately critical than deciding whether or not to give statins or lifestyle advice. In the present study MRI has shown similar prognostic accuracy to baseline 6-minutewalk test (AUC, 0.74) (47) .
Limitations
This is a single center study. Race has been shown to have an independent effect on RV volumes; however, the demographic of our population does not allow direct comparison with the published reference data (34) and we have not adjusted MRI data for race in this study. There is limited normative data on pulmonary vascular measurements such as PA relative area change, further work in this area is warranted to determine the influence of age, race and sex. This study shows that individual MRI metrics have limitations when used in the prognostic assessment of patients with PAH. Though improved accuracy can be achieved by combining MRI metrics with clinical data the PPV and NPV highlight that there are uncertainties in how best to use this investigation in the pulmonary hypertension clinic. MRI does have limitations including claustrophobia, pacemaker and metallic foreign bodies precluding in its use in approximately 5% of pulmonary hypertension cases (17) . Compared with other investigations such as the 6-minute-walk test it is more expensive and time consuming to perform and availability is more limited. Nonetheless the higher reproducibility of CMR compared Definition of abbreviations: IPAH = idiopathic pulmonary arterial hypertension; LHR = likelihood ratio; MRI = magnetic resonance imaging; NPV = negative predictive value; PAH = pulmonary arterial hypertension; PPV = positive predictive value; RV = right ventricular; Sens = sensitivity; Spec = specificity. Data in parentheses are 95% confidence intervals. The MRI model and MRI and demographic model were generated in the derivation cohort. For each variable, optimal thresholds were identified in the derivation cohort. 
